| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Disease-specific iPS cell lines were established from the patients with systemic lupus erythematosus (SLE). SLE-iPS cells were differentiated into dendritic cells with over secretion of type I interferon (IFN), which were thought to be a SLE pathological model in vitro. Whole exome analysis aidentified a novel rare variant associated with SLE. Functional analysis was performed using SLE-iPS cells, indicating that this variant was involved in excessive inflammatory cytokine production in SLE. In addition, we identified a new mechanism of exacerbation of mice model of lupus nephritis by the PADI4-JLP-p38 MAPK pathway in neutrophils, which was involved in renal migration. These results suggested that these mechanisms are expected as new therapeutic targets for SLE.
|
